CBD Treatment For Just One Week Can Significantly Reduce Anxiety

A new study has found that a hemp derived CBD product sold across the United States can alleviate moderate to severe anxiety symptoms in a short period of time after use.

The results of this open label clinical trial demonstrate that high content CBD products derived from Hanma, which are similar to those currently available on the market, are both safe and effective in treating anxiety disorders. ”
Researchers point out that standardized formulations of CBD products can help evaluate broader consumer behavior outside of laboratory environments.
It is reported that the trial included 12 adults with moderate to severe anxiety disorder, and all participants were required to quit marijuana before the experimental grouping and during the seven week study period.

The subjects took the CBD formula twice a day for six weeks, with a total daily intake of 30 milligrams.
At each visit, the subjects will be detected for the presence of cannabis metabolite THC-COOH using a gas chromatography-mass spectrometer.
Within one week after the start of the experiment, participants reported significant improvements in their anxiety symptoms, sleep, mood, quality of life, cognition, executive function, and memory.
Meanwhile, researchers pointed out that “the report shows that there were few side effects and no serious adverse events from the trial.” Anxiety disorder is one of the most common mental illnesses in the United States. Although selective serotonin reuptake inhibitors (SSRIs) are commonly used for treatment, new research findings offer hope for alternative therapies.
In this study, after only one week of treatment with CBD, patients’ anxiety symptoms were significantly reduced, “the authors wrote. The first-line treatment drugs for anxiety disorders, such as selective serotonin reuptake inhibitors (SSRIs), may take several weeks to show efficacy. ”The study was written by scientists from the Department of Psychiatry at Harvard Medical School and conducted at McLean Hospital, the largest psychiatric hospital at Harvard Medical School. The research results were published in the peer-reviewed scientific journal Biomedical in August 2025.

The research author revealed that scientists used a proprietary CBD formula provided by Charlotte’s Web, which contains trace amounts of THC.
Charlotte Network also provided funding for this study, but the funders did not participate in the research design, data collection, analysis, or interpretation, nor did they participate in the writing of the paper and the decision to publish the research results. ”The paper points out that the results of this clinical trial provide preliminary evidence that the use of this proprietary Hanma derived sublingual product with high CBD content across the spectrum can produce clinical improvements in patients with moderate to severe anxiety disorders, with fewer side effects.
This extends previous research suggesting that CBD may be effective for anxiety disorders. ”Although the experimental results indicate that CBD products have therapeutic effects and tolerability in patients with moderate to severe anxiety disorders, the authors caution that more research is still needed. Given the potential benefits observed in this trial, it is necessary to conduct a double-blind, placebo-controlled study on high CBD products derived from Hanma to obtain reliable data on the safety and efficacy of CBD containing products in treating anxiety disorders. ”The conclusion of this experiment extends previous research, indicating that CBD can effectively alleviate anxiety symptoms. For example, a study partially funded by the National Institute on Drug Abuse in the United States found that medical marijuana was associated with “significantly reduced self-reported anxiety and depression” compared to before patients began using marijuana therapy.
Another study funded by the federal agency found that a citrus flavored terpene in marijuana can help alleviate anxiety and paranoia associated with tetrahydrocannabinol (THC).

Researchers point out that this discovery may help maximize the therapeutic efficacy of THC and protect public health.
In 2024, a research paper supported by the industry on the potential anti anxiety effects of CBD found that oral CBD preparations can effectively treat mild to moderate anxiety, as well as related depression and poor sleep quality, and no serious adverse events were observed.
Another study published in the scientific journal Adolescent Health, Medicine, and Therapeutics in 2024 investigated medical marijuana patients under the age of 21 in the United States.
Researchers have found that minors and young people are typically eligible to participate in state marijuana pilot programs for the same reasons as older adults, who suffer from conditions including anxiety, post-traumatic stress disorder, and chronic pain.